EIF2AK3 and neoplasm: Interestingly, despite the marked suppression of pErk (Supplementary Fig. S8E), tumour cell viability was not significantly impaired by BRAFi and MEKi combination compared to the single drug treatments (Supplementary Fig. S8F).